[A26-28] Avapritinib (indolent systemic mastocytosis) – Addendum to Project A25-136
Last updated 07.05.2026
Project no.:
A26-28
Commission:
Commission awarded on 10.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
https://doi.org/10.60584/A26-28
| Project no. | Title | Status |
|---|---|---|
| A25-136 | Avapritinib (indolent systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07-05-2026 A G-BA decision was published.
G-BA documents on this decision